| pubmed-article:2510347 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2510347 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:2510347 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2510347 | lifeskim:mentions | umls-concept:C0032143 | lld:lifeskim |
| pubmed-article:2510347 | lifeskim:mentions | umls-concept:C0677626 | lld:lifeskim |
| pubmed-article:2510347 | lifeskim:mentions | umls-concept:C0699900 | lld:lifeskim |
| pubmed-article:2510347 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
| pubmed-article:2510347 | lifeskim:mentions | umls-concept:C0243125 | lld:lifeskim |
| pubmed-article:2510347 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2510347 | pubmed:dateCreated | 1989-12-18 | lld:pubmed |
| pubmed-article:2510347 | pubmed:abstractText | In this study, binding and degradation of tissue-type plasminogen activator (t-PA) by the human hepatoma cell line Hep G2 was investigated. Binding at 4 degrees C was time-dependent and reached a maximum after ca. 2 hours. Scatchard analysis of saturation experiments showed about 170,000 high affinity binding sites for t-PA per cell with an apparent Kd of 90 nM. These binding sites were calcium-dependent. Part of the binding to the hepatoma cells was non-saturable, owing to a large amount of low affinity binding sites which are at least partially located on the extracellular matrix of the cells. Competition with mannose- and galactose-terminated glycoproteins had no effect on total binding of 125I-t-PA. Degradation products of 125I-t-PA were found in the supernatant after a short lag phase and then increased linearly for at least 5 hours at 37 degrees C. Degradation could be inhibited by chloroquine, NH4Cl and NaN3. We conclude that the human hepatoma cell line Hep G2 has a specific binding mechanism for t-PA which is not mediated by known carbohydrate receptor systems. Binding is followed by cellular uptake and degradation in the lysosomes. | lld:pubmed |
| pubmed-article:2510347 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2510347 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2510347 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2510347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2510347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2510347 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2510347 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:2510347 | pubmed:issn | 0340-6245 | lld:pubmed |
| pubmed-article:2510347 | pubmed:author | pubmed-author:Van BerkelT... | lld:pubmed |
| pubmed-article:2510347 | pubmed:author | pubmed-author:RijkenD CDC | lld:pubmed |
| pubmed-article:2510347 | pubmed:author | pubmed-author:OtterMM | lld:pubmed |
| pubmed-article:2510347 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2510347 | pubmed:day | 29 | lld:pubmed |
| pubmed-article:2510347 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:2510347 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2510347 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2510347 | pubmed:pagination | 667-72 | lld:pubmed |
| pubmed-article:2510347 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2510347 | pubmed:meshHeading | pubmed-meshheading:2510347-... | lld:pubmed |
| pubmed-article:2510347 | pubmed:meshHeading | pubmed-meshheading:2510347-... | lld:pubmed |
| pubmed-article:2510347 | pubmed:meshHeading | pubmed-meshheading:2510347-... | lld:pubmed |
| pubmed-article:2510347 | pubmed:meshHeading | pubmed-meshheading:2510347-... | lld:pubmed |
| pubmed-article:2510347 | pubmed:meshHeading | pubmed-meshheading:2510347-... | lld:pubmed |
| pubmed-article:2510347 | pubmed:meshHeading | pubmed-meshheading:2510347-... | lld:pubmed |
| pubmed-article:2510347 | pubmed:meshHeading | pubmed-meshheading:2510347-... | lld:pubmed |
| pubmed-article:2510347 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2510347 | pubmed:articleTitle | Binding and degradation of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. | lld:pubmed |
| pubmed-article:2510347 | pubmed:affiliation | Gaubius Institute TNO, Leiden, The Netherlands. | lld:pubmed |
| pubmed-article:2510347 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2510347 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2510347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2510347 | lld:pubmed |
